Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kedalion Therapeutics Inc.

http://www.kedalionthera.com

Latest From Kedalion Therapeutics Inc.

Novartis's Kedalion Buy Could Revive Prospects For Xiidra

Getting hold of Kedalion's device that delivers topical drugs to the eye with comparable effect but with up to an 80% reduction in dose compared to standard eye drops bodes well for Novartis's ophthalmology business.

Commercial Companies

Venture Funding Deals: Orchard Brings Total To $291m

New $150m Series C round brings Orchard's tally to nearly $300m, just four months after the start-up acquired a portfolio of gene therapy candidates from GSK and eight months after a $110m round. Gritstone closed a Series C then announced an IPO filing, plus more late-summer VC rounds.

StartUps and SMEs Financing

Finance Watch: Rakuten Aspyrian Raises $150m VC Round For Laser-Activated Cancer Drugs

Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
UsernamePublicRestriction

Register